Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREAKWATER first-line encorafenib + cetuximab with or without chemotherapy versus standard treatment in metastatic BRAF V600E-mutant colorectal cancer
CTR20212641Phase 3Active
- Sponsor
- Pfizer
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of encorafenib, cetuximab in colorectal cancer (CRC), sponsored by Pfizer. Started Mar 2022; status: active.
02
Drugs
encorafenibcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20212641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212641.